Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”
(Source: Drugs)
Source: Drugs - December 18, 2023 Category: Drugs & Pharmacology Source Type: research
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis
ConclusionsThe evidence clearly indicates that the pharmacological treatment approaches differ between TMD-M and TMD-J. Therefore, it is of great importance to first try to uncover each patient ’s individual and multifactorial etiology and then employ a multifaceted treatment strategy, including pharmacological treatment approaches. (Source: Drugs)
Source: Drugs - December 16, 2023 Category: Drugs & Pharmacology Source Type: research
Vamorolone: First Approval
This article summarizes the milestones in the development of vamorolone leading to this first approval for DMD. (Source: Drugs)
Source: Drugs - December 16, 2023 Category: Drugs & Pharmacology Source Type: research
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis
ConclusionsThe evidence clearly indicates that the pharmacological treatment approaches differ between TMD-M and TMD-J. Therefore, it is of great importance to first try to uncover each patient ’s individual and multifactorial etiology and then employ a multifaceted treatment strategy, including pharmacological treatment approaches. (Source: Drugs)
Source: Drugs - December 16, 2023 Category: Drugs & Pharmacology Source Type: research
Vamorolone: First Approval
This article summarizes the milestones in the development of vamorolone leading to this first approval for DMD. (Source: Drugs)
Source: Drugs - December 16, 2023 Category: Drugs & Pharmacology Source Type: research
Zilucoplan: First Approval
This article summarises the milestones in the development of zilucoplan leading to this first approval for gMG. (Source: Drugs)
Source: Drugs - December 14, 2023 Category: Drugs & Pharmacology Source Type: research
New Therapies on the Horizon for Primary Biliary Cholangitis
AbstractPrimary biliary cholangitis (PBC) is a chronic cholestatic liver disease that can progress to cirrhosis and hepatic failure if left untreated. Ursodeoxycholic acid (UDCA) was introduced as a first-line drug for PBC around 1990; it remarkably improved patient outcomes, leading to the nomenclature change of PBC in 2015, from primary biliary “cirrhosis” to primary biliary “cholangitis.” Nevertheless, 20–30% of patients exhibit an incomplete response to UDCA, resulting in significantly worse outcomes compared to those with a complete response. Therefore, improving the long-term outcomes of patients with an in...
Source: Drugs - December 12, 2023 Category: Drugs & Pharmacology Source Type: research
HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic
AbstractHuman immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) provides a critical intervention toward ending the HIV epidemic and protecting people with reasons to utilize PrEP. PrEP options continue to expand as new administration modalities offer the potential to tailor PrEP use for individual success. We have provided the evidence for new and emerging antiretroviral agents for PrEP (cabotegravir, lenacapavir, dapivirine, and broadly neutralizing antibodies), divided into pharmacology, animal model, and human data, accompanied by a summary and suggested place in therapy. Cabotegravir is a US Food and Drug Ad...
Source: Drugs - December 11, 2023 Category: Drugs & Pharmacology Source Type: research
Gepirone Extended-Release: First Approval
This article summarizes the milestones in the development of gepirone ER leading to this first approval for the treatment of adults with MDD. (Source: Drugs)
Source: Drugs - December 11, 2023 Category: Drugs & Pharmacology Source Type: research
HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic
AbstractHuman immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) provides a critical intervention toward ending the HIV epidemic and protecting people with reasons to utilize PrEP. PrEP options continue to expand as new administration modalities offer the potential to tailor PrEP use for individual success. We have provided the evidence for new and emerging antiretroviral agents for PrEP (cabotegravir, lenacapavir, dapivirine, and broadly neutralizing antibodies), divided into pharmacology, animal model, and human data, accompanied by a summary and suggested place in therapy. Cabotegravir is a US Food and Drug Ad...
Source: Drugs - December 11, 2023 Category: Drugs & Pharmacology Source Type: research
Nedosiran: First Approval
This article summarizes the milestones in the development of nedosiran leading to this first approval for PH1. (Source: Drugs)
Source: Drugs - December 7, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
ConclusionThe travoprost intraocular implant demonstrated robust IOP-lowering and substantially reduced topical IOP-lowering medication burden for up to 36 months following a single administration, while maintaining a favorable safety profile. The travoprost intraocular implant promises to be a meaningful addition to the interventional glaucoma armamentarium by addressing the key shortcomings of topical IOP-lowering medications, including low adherence and topical side effects while controlling IOP for up to 36 months.Trial RegistryClinicalTrials.gov identifier NCT02754596 registered 28 April 2016. (Source: Drugs)
Source: Drugs - December 7, 2023 Category: Drugs & Pharmacology Source Type: research
